Telmisartan to prevent recurrent stroke and cardiovascular events

Yusuf, Salim, Diener, Hans-Christoph, Sacco, Ralph L., Cotton, Daniel, Ounpuu, Stephanie, Lawton, William A., Palesch, Yuko, Martin, Renée H., Albers, Gregory W., Bath, Philip M.W., Bornstein, Natan, Chan, Bernard P.L., Chen, Sien-Tsong, Cunha, Luis, Dahlöf, Björn, De Keyser, Jacques, Donnan, Geoffrey A., Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Hillbrich, Lutz, Kaste, Markku, Lu, Chuanzhen, Machnig, Thomas, Pais, Prem, Roberts, Robin, Skvortsova, Veronika, Teal, Philip, Toni, Danilo, Vandermaelen, Cam, Voight, Thor, Weber, Michael and Yoon, Byung-Woo (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine, 359 (12). pp. 1225-1237. ISSN 0028-4793

Full text not available from this repository.



Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent

stroke. In addition, inhibition of the renin–angiotensin system in high-risk patients

reduces the rate of subsequent cardiovascular events, including stroke. However, the

effect of lowering of blood pressure with a renin–angiotensin system inhibitor soon

after a stroke has not been clearly established. We evaluated the effects of therapy

with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.


In a multicenter trial involving 20,332 patients who recently had an ischemic stroke,

we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive

placebo. The primary outcome was recurrent stroke. Secondary outcomes were

major cardiovascular events (death from cardiovascular causes, recurrent stroke,

myocardial infarction, or new or worsening heart failure) and new-onset diabetes.


The median interval from stroke to randomization was 15 days. During a mean followup

of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan

group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group

and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in

the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P = 0.23). Major

cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and

1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01;

P = 0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the

placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P = 0.10).


Therapy with telmisartan initiated soon after an ischemic stroke and continued for

2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular

events, or diabetes. ( number, NCT00153062.)

Item Type: Article
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Clinical Neuroscience
Identification Number:
Depositing User: Sayers, Hazel
Date Deposited: 11 Sep 2008 13:33
Last Modified: 04 May 2020 16:27

Actions (Archive Staff Only)

Edit View Edit View